Monoclonal Antibodies: Insight Review

Monoclonal antibodies (mAbs) are a significant achievement in biotechnology and medicine. Kohler and Milstein's Nobel Prize-winning research on murine hybridoma technology in 1975 resulted in the development of mAbs, which are designed to function as substitute antibodies that can restore, augment, or mimic the immune system's attack on cancer cells and other infections. In 1986, the FDA approved the first monoclonal antibody, Orthoclone OKT3® (muromonab-CD3), a huge step forward in antibody research and development. Monoclonal antibodies are glycoproteins produced by identical B cell clones that target a specific antigen. They are made up of heavy and light chains that form a Y shape. Variable regions, or antigen-binding sites, are highly selective to their target antigens. The constant areas mediate effector actions such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity. Monoclonal antibodies work by attaching to specific antigens on target cells' surfaces, neutralizing or destroying them. This can happen through either direct processes, such as inhibiting receptor-ligand interactions, or indirect mechanisms, such as attracting immune cells to cause cell death. Monoclonal antibodies are created by hybridoma technology or phage display. The hybridoma approach creates hybridomas, which are permanent antibody factories, by fusing B cells and myeloma cells. Phage display is a molecular approach that involves expressing antibody fragments on the surface of bacteriophages to select high-affinity antibodies.The future of monoclonal antibodies depends in improving their selectivity while decreasing immunogenicity through humanization and engineering. Biotechnology advancements will broaden their use in a variety of therapeutic areas, including infectious diseases, cardiovascular ailments, and neurological problems.